GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » EBIT

DuoGenic StemCells (ROCO:7607) EBIT : NT$-56.11 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells EBIT?

DuoGenic StemCells's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-33.32 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-56.11 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. DuoGenic StemCells's annualized ROC % for the quarter that ended in Jun. 2024 was -175.12%. DuoGenic StemCells's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -210.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. DuoGenic StemCells's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -7.27%.

DuoGenic StemCells EBIT Historical Data

The historical data trend for DuoGenic StemCells's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells EBIT Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23
EBIT
-22.80 -33.67 -44.91

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial -14.43 -19.24 -22.12 -22.79 -33.32

Competitive Comparison of DuoGenic StemCells's EBIT

For the Biotechnology subindustry, DuoGenic StemCells's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuoGenic StemCells's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's EV-to-EBIT falls into.


DuoGenic StemCells EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-56.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells  (ROCO:7607) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

DuoGenic StemCells's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-65.49 * ( 1 - 3.4% )/( (39.41 + 32.841)/ 2 )
=-63.26334/36.1255
=-175.12 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=94.002 - 8.296 - ( 46.296 - max(0, 10.354 - 66.689+46.296))
=39.41

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=59.785 - 6.629 - ( 20.315 - max(0, 8.934 - 33.352+20.315))
=32.841

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

DuoGenic StemCells's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-66.644/( ( (23.653 + max(11.947, 0)) + (21.349 + max(6.283, 0)) )/ 2 )
=-66.644/( ( 35.6 + 27.632 )/ 2 )
=-66.644/31.616
=-210.79 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.429 + 11.824 + 5.109) - (8.296 + 0 + 0.119)
=11.947

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.988 + 4.684 + 5.359) - (6.629 + 0 + 0.119)
=6.283

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

DuoGenic StemCells's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-56.107/771.810
=-7.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells EBIT Related Terms

Thank you for viewing the detailed overview of DuoGenic StemCells's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

DuoGenic StemCells Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
Website
https://www.dgsc.com.tw
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines